002675.SZ
东诚药业
SZSE · Healthcare · C 制造业 · CN
CNY 12.77
−2.07%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
27.7x
EV/EBITDA
27.9x
Market Cap
CNY 10.53B
MomentumView details →
1D Return
−2.07%
YTD Return
−7.28%
RSI (14)
44.2
ValuationView details →
P/E (Fwd)
27.7x
EV/EBITDA
27.9x
Market Cap
CNY 10.53B
RSI (14)
44.2
MomentumView details →
1D Return
−2.07%
YTD Return
−7.28%
Similar companies
Latest newsMore news →
Dongcheng Pharmaceutical announced that as of August 31, 2026, it had repurchased 7.3995 million shares (0.90% of total shares) for a total of 100 million yuan under its ongoing buyback program.3d agoDongcheng Pharmaceutical's wholly-owned subsidiary Andike signed equity transfer agreements to acquire 100% of Kunming Cyclotron and 100% of Sichuan Cyclotron for RMB 40.2 million and RMB 40 million respectively, and to sell its 45% stake in Guangdong Cyclotron for RMB 121 million.12d agoDongcheng Pharmaceutical's subsidiary Andike received a radioactive drug production license from Shanxi Provincial Drug Administration, allowing its Shanxi Jinzhong nuclear medicine production center to begin operations, producing fludeoxyglucose F-18 injection.22d ago